Drug Search Results
More Filters [+]

AI-09

Alternative Names: ai-09, ai 09, ai09, A1-09, A109
Latest Update: 2024-01-25
Latest Update Note: Clinical Trial Update

Product Description

AI-09 is an injectable Botulinum for Glabellar Lines. AI-09 employs a proprietary technology that allows an injectable botulinum to be formulated as a convenient, ready-to-use liquid product, instead of requiring reconstitution with saline prior to use. (Sourced from: http://www.eirionthera.com/)

Mechanisms of Action: Unknown

Novel Mechanism: No

Modality: Large Molecule

Route of Administration: Intramuscular

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Eirion
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for AI-09

Countries in Clinic: United States

Active Clinical Trial Count: 1

Highest Development Phases

Phase 2: Glabellar Reflex

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

AI-09-GL-101

P2

Active, not recruiting

Glabellar Reflex

2024-05-01

34%

Recent News Events